AML (ACUTE MYELOGENOUS LEUKEMIA)
Clinical trials for AML (ACUTE MYELOGENOUS LEUKEMIA) explained in plain language.
Never miss a new study
Get alerted when new AML (ACUTE MYELOGENOUS LEUKEMIA) trials appear
Sign up with your email to follow new studies for AML (ACUTE MYELOGENOUS LEUKEMIA), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to stop AML from coming back
Disease control ENROLLING_BY_INVITATIONThis study tests whether adding venetoclax to standard chemotherapy can help keep acute myeloid leukemia (AML) from returning. It is for adults aged 18 to 65 who are already in remission after initial treatment. The goal is to see if the combination leads to fewer cancer cells le…
Matched conditions: AML (ACUTE MYELOGENOUS LEUKEMIA)
Phase: PHASE2, PHASE3 • Sponsor: Guangdong Second Provincial General Hospital • Aim: Disease control
Last updated May 17, 2026 04:33 UTC
-
CAR-T therapy: what happens years later? new study tracks Long-Term risks
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows about 178 people who previously received an experimental AvenCell CAR-T cell therapy for blood cancers or prostate cancer. Researchers will monitor participants for years to check for delayed side effects, such as new cancers, nerve disorders, or severe infecti…
Matched conditions: AML (ACUTE MYELOGENOUS LEUKEMIA)
Sponsor: AvenCell Therapeutics, Inc. • Aim: Knowledge-focused
Last updated May 15, 2026 11:56 UTC